Oculocutaneous albinism type 1a is a rare genetic condition that affects the skin, hair, and eyes from birth and throughout life. People with Oculocutaneous albinism type 1a have very light skin and hair and reduced eye pigment, and they may notice light sensitivity and blurry vision. Doctors describe this as a lifelong, nonprogressive form of albinism that is usually identified in infancy or early childhood. The condition itself does not shorten life, but vision differences can affect school, work, and daily activities. Care focuses on sun protection, low-vision support, regular eye care, and educational accommodations.
Overview
Oculocutaneous albinism type 1aSymptoms
In oculocutaneous albinism type 1A, signs are evident at birth: very light skin, white or very pale hair, and light-colored eyes. Eye features include reduced vision, involuntary eye movements, and light sensitivity; skin burns easily without protection.
Outlook and prognosis
Most people with Oculocutaneous albinism type 1a live a typical lifespan. Vision differences are lifelong, but early low‑vision support, sun protection, and regular eye and skin checks help many lead independent, active lives. Skin cancer risk is higher without careful UV protection.
Causes and risk factors
Genetic causes of Oculocutaneous albinism type 1a involve TYR mutations that stop tyrosinase, present from birth and inherited autosomal recessively. Risk rises when both parents are carriers; some groups have higher carrier rates. Sun exposure affects complications, not cause.
Genetic influences
Genetics are central in Oculocutaneous albinism type 1a. Inherited changes in the TYR gene stop melanin production entirely, leading to very light skin, hair, and eyes from birth. It’s autosomal recessive, so both parents usually carry the variant.
Diagnosis
Doctors suspect Oculocutaneous albinism type 1a from very light skin and hair at birth plus typical eye findings. An eye exam and specialized testing support the diagnosis. Genetic diagnosis of Oculocutaneous albinism type 1a confirms TYR gene changes.
Treatment and drugs
Treatment for oculocutaneous albinism type 1a focuses on protecting skin and eyes and maximizing vision. This often includes high‑SPF sunscreen and UV‑blocking clothing, prescription glasses or contacts, tinted lenses, and low‑vision aids. Regular eye care and skin checks are important.
Symptoms
Bright light may feel harsh and print can look less crisp, especially in classrooms or outdoors. In medical terms, this is oculocutaneous albinism type 1a; in everyday life, it shows up as very light skin, hair, and eye coloring plus vision differences. Many early features of Oculocutaneous albinism type 1a are noticeable in infancy, including pale coloring and rapid eye movements. Features can vary in severity, and supports like hats, sunglasses, and low-vision aids often make activities easier.
Skin is very pale and does not tan, and hair, brows, and lashes are white or almost white. This is constant in OCA1A because the body makes little to no melanin. Sunburn can happen quickly without protection.
Bright sunlight can sting or feel overwhelming, and skin burns easily. Wide-brimmed hats, UV-blocking sunglasses, and high-SPF sunscreen help protect the skin and eyes.
The irises are very light and can let extra light into the eye, causing glare. Eyes may look blue, gray, or very light, and sometimes appear pinkish in certain lighting.
Involuntary, quick eye movements often begin in infancy. The world may seem to shimmer or bounce when trying to fix on small details. Some people find a head turn or tilt helps steady the view.
How people usually first notice Oculocutaneous albinism type 1a?
Many families first notice oculocutaneous albinism type 1a (OCA1A) at birth because a baby’s hair, eyebrows, eyelashes, and skin appear very light compared with relatives, and the irises may look pale with eyes that seem sensitive to light. In the first weeks to months, caregivers and doctors often spot constant small eye movements (nystagmus) and reduced visual focus, which prompt an eye exam; these are among the most common first signs of OCA1A. Pediatricians or ophthalmologists typically confirm the diagnosis by noting absent pigment in the hair and skin along with eye findings and, when available, genetic testing that shows a TYR gene change that prevents melanin production.
Types of Oculocutaneous albinism type 1a
People with Oculocutaneous albinism type 1a live with a genetic condition that affects how much pigment their skin, hair, and eyes can make. In this subtype, the enzyme that normally helps produce melanin does not function, leading to little to no pigment from birth. Not everyone will experience every type. Clinicians often group these into clinical variants, which describe how specific gene changes relate to pigment levels and vision features.
OCA1A classic
This variant involves no detectable melanin production throughout life. Skin and hair remain very light or white, and eyes have reduced pigment leading to light sensitivity and vision differences.
OCA1A with modifiers
Some people inherit additional genetic factors that subtly influence features without restoring melanin. Appearance and vision needs are still consistent with Oculocutaneous albinism type 1a, but day‑to‑day light sensitivity or nystagmus may vary.
Molecular subgroups
Different TYR gene mutations can be grouped by how they disrupt the enzyme’s structure or processing. These molecular differences help confirm the diagnosis and guide family counseling, even though outward features remain within the OCA1A spectrum and not distinct types.
What genetics can tell you about symptoms
People with oculocutaneous albinism type 1a have little to no melanin because changes in the TYR gene shut down tyrosinase, the enzyme that starts pigment production. This leads to very light skin and hair, reduced vision, nystagmus, light sensitivity, and foveal underdevelopment.
Causes and risk factors
In oculocutaneous albinism type 1a, both TYR gene copies have changes that stop melanin production. It is inherited in an autosomal recessive pattern, so two carrier parents have a 25% chance in each pregnancy. Risk factors for oculocutaneous albinism type 1a include family history, shared ancestry patterns, and parents being related by blood. Some risks are written in our DNA, passed down through families. Environment and lifestyle do not cause oculocutaneous albinism type 1a, but sun exposure and eye strain can raise skin and vision problems over time.
Environmental and biological risk factors
Environmental and biological risk factors for oculocutaneous albinism type 1a appear limited. Some risks are carried inside the body, others come from the world around us. So far, studies have not linked common environmental exposures, parental age, or typical pregnancy illnesses to a higher chance of oculocutaneous albinism type 1a. Researchers continue to look for external influences, but clear triggers have not been identified.
Advanced maternal or paternal age has not been shown to increase the chance of oculocutaneous albinism type 1a. Available studies do not show a consistent pattern. Ongoing research monitors age-related effects.
Common health conditions in pregnancy, such as diabetes or thyroid disorders, have not been clearly linked to this condition. Regular prenatal care remains important for overall pregnancy health. Current evidence does not show a higher likelihood.
Typical maternal infections have not been associated with a higher chance of oculocutaneous albinism type 1a. Severe infections can affect pregnancy in other ways, but no specific tie to this condition has been found.
Most medications taken under medical guidance during pregnancy have not been tied to oculocutaneous albinism type 1a. Always review medicines with your prenatal team.
Genetic risk factors
In Oculocutaneous albinism type 1a (OCA1A), risk starts with changes in the TYR gene that stop the pigment-making enzyme from working. People are affected when both copies of TYR carry these changes, inherited one from each parent. Carrying a genetic change doesn’t guarantee the condition will appear—single-copy carriers typically have no symptoms. When discussing the genetic causes of Oculocutaneous albinism type 1a, family history and a partner’s carrier status shape the chances for a child.
TYR gene changes: Changes in the TYR gene cause OCA1A by blocking the pigment-making enzyme. Most people develop OCA1A when both TYR copies have loss-of-function changes inherited from each parent. Genetic testing can find these changes and confirm the diagnosis.
Complete enzyme loss: OCA1A occurs when TYR changes remove enzyme activity entirely, leading to no melanin production. TYR changes that leave some activity usually cause other OCA types, not Oculocutaneous albinism type 1a.
Autosomal recessive pattern: OCA1A follows a recessive inheritance pattern. When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of OCA1A. Unaffected siblings may still be carriers.
Family history: A prior child with OCA1A or known TYR changes in the family increases the chance another child will be affected. Relatives may be carriers even if they have typical coloring.
Ancestry patterns: In some communities, specific TYR changes are more common due to founder effects. This can raise the local carrier rate and the odds that two carriers have a child with Oculocutaneous albinism type 1a.
Parental relatedness: When parents are related by blood, they are more likely to carry the same TYR change. This raises the chance of OCA1A in their children.
Partner carrier status: People living with OCA1A will pass one TYR change to all of their children. If a partner is also a carrier, each child has a 50% chance of OCA1A and a 50% chance to be a carrier. If the partner is not a carrier, children will not have OCA1A but will be carriers.
Lifestyle risk factors
Oculocutaneous albinism type 1a is a genetic condition; lifestyle habits do not cause it, but they can strongly influence symptoms, day‑to‑day function, and risks like sunburn and skin cancer. Understanding how lifestyle affects Oculocutaneous albinism type 1a helps you target practical changes that reduce UV damage and visual strain. Below are lifestyle risk factors for Oculocutaneous albinism type 1a and ways choices can raise or lower complications.
Time in direct sun without protection greatly increases sunburn and skin cancer risk. Consistent shade, protective clothing, and sun-smart planning reduce cumulative UV damage.
Skipping wide‑brim hats, UPF shirts, and long sleeves exposes more skin and eyes to UV. UV‑blocking fabrics can cut exposure dramatically and lower burn and cancer risk.
Going without wraparound, UV400 sunglasses increases photophobia, glare, and ocular surface irritation. Polarized, large‑frame lenses reduce glare and improve visual comfort outdoors.
Infrequent use or low‑SPF products allow UV injury to accumulate. Broad‑spectrum SPF 30–50+, applied generously and reapplied every 2 hours (and after water/sweat), lowers burn risk.
Risk prevention
You can’t prevent oculocutaneous albinism type 1a itself, since it’s inherited, but you can lower the chance of complications and protect vision and skin. Daily sun safety, early eye care, and practical adjustments at home and school make a real difference. Families planning a pregnancy may also want to explore genetic counseling for future risk. Prevention works best when combined with regular check-ups.
Use broad-spectrum sunscreen, sun-protective clothing, and a wide-brim hat to prevent burns and lower skin cancer risk. Seek shade and avoid peak midday sun when possible.
Wear UV-blocking sunglasses and consider hat brims to cut glare and light sensitivity. This helps comfort and may reduce eye strain for people with oculocutaneous albinism type 1a.
Do regular self-checks and schedule dermatology visits to spot new or changing spots early. Early treatment lowers the chance of serious skin problems.
See a pediatric eye specialist early if you notice nystagmus, squinting, or other early symptoms of oculocutaneous albinism type 1a. Glasses, low-vision aids, and targeted therapies can support development and reduce secondary issues like amblyopia.
Transmission
Oculocutaneous albinism type 1a is not contagious—you can’t catch it from someone or spread it through close contact. Instead, it is inherited in an autosomal recessive way: when both parents are carriers (each has one changed copy of the gene), every pregnancy has a 25% (1 in 4) chance of a child with Oculocutaneous albinism type 1a, a 50% (1 in 2) chance of a carrier, and a 25% (1 in 4) chance of neither copy changed.
Most cases occur when both parents are carriers; in rare situations a new genetic change is involved, and if one parent has the condition and the other is a carrier, each child has a 50% (1 in 2) chance of being affected. If you’re wondering about the genetic transmission of Oculocutaneous albinism type 1a or how Oculocutaneous albinism type 1a is inherited, genetic counseling and carrier testing can clarify your family’s risks.
When to test your genes
Genetic testing is helpful if you or a child have very light hair/skin from birth with absent pigment, nystagmus, reduced vision, or a family history of OCA. Test early—ideally in infancy or childhood—to confirm the diagnosis, guide eye care, sun protection, and school supports. Consider testing before pregnancy for carrier screening and family planning.
Diagnosis
Oculocutaneous albinism type 1a is usually identified early based on very light skin and hair from birth, along with eye findings such as light sensitivity and rapid eye movements. Doctors usually begin with a careful look at appearance and vision, then confirm the cause with targeted tests. Because this is a genetic condition, testing can distinguish OCA1A from other types of albinism and related syndromes. Early recognition allows families to plan vision care and sun protection from the start.
Clinicians look for very light hair and skin that do not tan, plus pale eyelashes and eyebrows. These visible features in the first weeks of life raise suspicion for albinism.
An eye doctor checks for reduced eye pigment, light sensitivity, and rapid eye movements. They also assess focusing, eye alignment, and early signs of reduced clarity of central vision.
Age-appropriate tests estimate visual acuity and contrast sensitivity. Even simple fixation and tracking checks in infants can show reduced vision compared with typical development.
A painless scan (optical coherence tomography) looks at the center of the retina to see if it is underdeveloped. This imaging finding supports albinism when combined with clinical features.
Stages of Oculocutaneous albinism type 1a
Oculocutaneous albinism type 1a does not have defined progression stages. It is present from birth and generally does not change over time, so features like very light skin and hair remain, while vision differences are usually stable. Different tests may be suggested to help confirm the diagnosis, such as an eye exam, a review of skin and hair pigmentation, and genetic testing. Doctors often monitor Oculocutaneous albinism type 1a with regular vision checks and sun-safety planning, and early symptoms of Oculocutaneous albinism type 1a can include very light hair and skin at birth and eye movements noticed in infancy.
Outlook and prognosis
Daily routines often adapt as people with Oculocutaneous albinism type 1a find ways to protect their skin and support vision—broad‑brim hats, high‑SPF sunscreen, sunglasses, and sitting closer to a screen or board can help. Everyone’s journey looks a little different. Vision is reduced from birth and stays relatively stable over time, and eye movements or light sensitivity may persist, but low‑vision tools and regular eye care can improve day‑to‑day function. The outlook is not the same for everyone, but many living with Oculocutaneous albinism type 1a build reliable routines for school, work, and hobbies with thoughtful accommodations.
Looking at the long-term picture can be helpful. Oculocutaneous albinism type 1a does not shorten life expectancy by itself; the main medical risks are sunburn and a higher chance of skin cancers after years of UV exposure. With ongoing care, many people maintain healthy skin by pairing shade, clothing barriers, and sunscreen, and by getting regular skin checks to catch changes early. For some, early symptoms of Oculocutaneous albinism type 1a—like strong light sensitivity, squinting, or difficulty seeing detail—ease a bit as they learn strategies and receive low‑vision support, though vision typically remains in the reduced range.
Understanding the prognosis can guide planning and help you focus on what you can influence: eye care, UV protection, school or workplace accommodations, and regular check‑ins with dermatology and ophthalmology. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. People living with Oculocutaneous albinism type 1a generally do well when support is in place, and most can participate fully in education, employment, and community life with adjustments tailored to their needs. Talk with your doctor about what your personal outlook might look like, including timing for eye therapies, low‑vision services, and a sensible skin‑screening schedule.
Long-term effects
Oculocutaneous albinism type 1a is present from birth and its effects tend to be lifelong rather than progressively worsening. Vision differences are usually stable after early childhood, while skin and hair remain very light across the lifespan. Long-term effects vary widely, but most center on eyesight and sun-related skin health. Most people otherwise have typical growth, learning potential, and life expectancy.
Lifelong reduced visual sharpness is common due to the way the center of the retina develops. Many have best-corrected acuity around 6/30 to 6/120 (20/100 to 20/400). This tends to remain relatively stable over time.
Involuntary eye movements often start in infancy and may soften with age. These movements can make focusing and tracking lines of text harder. Early signs of Oculocutaneous albinism type 1a, like rapid eye movements and light sensitivity, usually appear in infancy.
Eye misalignment can occur and may reduce depth perception. This can make judging distances or catching a ball less precise. Effects often persist into adulthood.
Bright light and glare can feel uncomfortable indoors and outdoors. This sensitivity is lifelong in Oculocutaneous albinism type 1a. It can compound reading or outdoor visibility challenges.
How is it to live with Oculocutaneous albinism type 1a?
Daily life with oculocutaneous albinism type 1a often revolves around protecting the eyes and skin and finding comfortable ways to navigate bright light. Many people wear UV-blocking sunglasses, wide-brim hats, and long sleeves, choose shaded routes, and use high-contrast, large-print tools or screen magnification for reading and school or work tasks. Friends, family, and classmates may notice someone sitting closer to the board, adjusting lighting, or opting out of midday sun; understanding and small accommodations—like flexible seating, accessible materials, and planning outdoor time—make a big difference. With these supports, most people build routines that keep them safe, reduce eye strain, and allow full participation in school, work, sports, and social life.
Treatment and drugs
Oculocutaneous albinism type 1a (OCA1A) is managed by protecting the skin and eyes from light and preventing complications, since current treatments can’t restore pigment. Daily sun protection is key: broad-spectrum sunscreen (SPF 50+), UV-protective clothing, wide‑brim hats, and seeking shade; regular skin checks help catch sun damage or skin cancers early. For vision, people with OCA1A often benefit from prescription glasses, tinted lenses or transition lenses, polarized sunglasses, and sometimes low‑vision aids like magnifiers or telescopic lenses; vision therapy and educational supports can improve comfort and reading or school tasks. Eye doctors may treat nystagmus or a head turn with prisms, and in selected cases consider surgery to improve head posture or eye alignment; if amblyopia is present, patching in childhood may help. Supportive care can make a real difference in how you feel day to day, and routine follow‑up with dermatology, ophthalmology, and primary care helps tailor protection and tools over time.
Non-drug treatment
Oculocutaneous albinism type 1a affects skin and eye pigment, which can raise sun sensitivity and reduce vision clarity in daily life. Recognizing early symptoms of Oculocutaneous albinism type 1a lets families start practical steps to protect skin and support vision. Non-drug treatments often lay the foundation for long-term care, from sun safety to vision tools. The options below can be tailored with your eye doctor, dermatologist, and school team.
Seek shade during peak sun, especially midday. Plan outdoor time in early morning or late afternoon.
Wear long sleeves, trousers, and UPF-rated fabrics to block UV. Lightweight, tightly woven materials help keep cool while protecting skin.
Use SPF 50+ broad-spectrum on exposed skin, including ears and scalp edges. Reapply every 2 hours and after swimming or sweating.
Choose wraparound sunglasses labeled UV400 or 100% UV protection. Larger frames and side shields cut glare and protect the eyes.
Your genes may have an impact on how drugs work for you
Even when two people share Oculocutaneous albinism type 1a, their genes can change how they absorb, break down, and respond to medicines for vision, skin protection, or surgery. Pharmacogenetic testing can guide safer dosing and drug choices, reducing side effects.
Pharmacological treatments
There’s no medicine that can restore pigment production in Oculocutaneous albinism type 1a, but a few drug options help protect skin, ease eye comfort, or manage related issues. These can lower sun damage risk and make day-to-day vision tasks a bit easier, especially when early symptoms of Oculocutaneous albinism type 1a like light sensitivity are noticeable. Doses and choices are individualized, and some options are off-label. Alongside drug therapy, sun-protective clothing and regular eye care remain important.
Broad-spectrum sunscreens with zinc oxide or titanium dioxide (SPF 50+) help block UVA/UVB and lower sunburn and skin cancer risk. Reapply every 2 hours and after swimming or sweating. Choose fragrance-free options if your skin is sensitive.
Nicotinamide (niacinamide) 500 mg twice daily has been shown to reduce some non-melanoma skin cancers in high-risk adults. Discuss if it’s appropriate for your risk profile and other medicines. Not everyone responds to the same medication in the same way.
Cholecalciferol can support bone health when sun exposure is limited. Typical daily doses range from 800–2,000 IU (20–50 micrograms), guided by blood tests and your clinician’s advice. Do not exceed recommended doses without medical guidance.
Preservative-free artificial tears (for example, carboxymethylcellulose or hyaluronic acid drops) can ease dryness and light sensitivity. They are safe for frequent use and can be paired with tinted lenses. Report any persistent irritation to your eye doctor.
Genetic influences
In oculocutaneous albinism type 1a (OCA1A), both copies of a pigment‑making gene must have a harmful change for the condition to appear (a pattern called autosomal recessive). A “carrier” means you hold the gene change but may not show symptoms. When two carriers have a child, each pregnancy has a 25% (1 in 4) chance of OCA1A, a 50% chance the child will be a carrier, and a 25% chance of neither. The gene involved, called TYR, makes an enzyme that starts the melanin‑making process; in OCA1A, certain changes switch this enzyme off completely, so melanin isn’t produced. That genetic shutdown is why people with OCA1A usually have very light skin and hair from birth and minimal darkening over time compared with other albinism types. Genetic testing for Oculocutaneous albinism type 1a can confirm the TYR changes and help guide family planning and counseling.
Is Oculocutaneous albinism type 1a genetic?
Genetics are central in Oculocutaneous albinism type 1a. Inherited changes in the TYR gene stop melanin production entirely, leading to very light skin, hair, and eyes from birth. It’s autosomal recessive, so both parents usually carry the variant.
Pharmacogenetics—how genetics influence drug effects
Because Oculocutaneous albinism type 1a involves little to no working tyrosinase, treatments that try to “turn up” this enzyme or feed its usual building blocks are unlikely to increase pigment. Genetics can still guide care: confirming the exact TYR gene changes helps set expectations and can determine whether future gene-based therapies or clinical trials are a good fit as research progresses. Genetics is only one factor in medication response, and the TYR changes seen in OCA1A don’t typically affect the liver enzymes that process most common prescriptions, so routine drug dosing for unrelated conditions is usually the same as for others. There are no well-established pharmacogenetic cautions specific to OCA1A for medicines sometimes used to manage symptoms (like treatments for nystagmus) beyond standard prescribing. If you’re exploring treatment options for Oculocutaneous albinism type 1a, genetic testing that identifies your TYR variants can help your care team match you with appropriate trials as they become available. It’s also wise to check with your specialist before trying any supplements or products marketed to boost pigmentation, since they’re unlikely to work in OCA1A and may have downsides.
Interactions with other conditions
Day-to-day, people with Oculocutaneous albinism type 1a (OCA1A) often find that extreme light sensitivity and low vision can interact with other health issues. Doctors call it a “comorbidity” when two conditions occur together, and the most important to watch is how OCA1A’s lack of protective pigment raises the lifetime risk of sun damage and skin cancers; this risk can be amplified by medicines that make skin more light-sensitive, such as certain antibiotics, diuretics, or acne treatments. Because early symptoms of Oculocutaneous albinism type 1a include intense light sensitivity, migraines or light-triggered headaches—if present—may flare more easily, and tinted lenses or careful light control can help. Avoiding sun for skin protection may also lower vitamin D levels over time, especially in northern climates, so periodic checks and supplements when needed can support bone health. Vision differences from OCA1A can coexist with unrelated eye diseases like cataract or glaucoma later in life, and having both can compound glare and reading strain, making regular eye care important. If someone with “albinism” also has easy bruising or bleeding, frequent infections, or lung or bowel problems, that pattern suggests a different, syndromic form (such as Hermansky–Pudlak or Chediak–Higashi) rather than OCA1A, and it’s worth prompt evaluation to guide the right care.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns that certain children were born with very light skin and hair, and their eyes seemed extra sensitive to light. In some families, this happened across generations, while in others it appeared unexpectedly. Everyday life highlighted the differences: a baby who never tanned, a school-age child who squinted outdoors even on cloudy days, a teen whose hair stayed white despite getting older.
From early theories to modern research, the story of Oculocutaneous albinism type 1a has unfolded step by step. Early descriptions grouped many forms of albinism together because they looked similar on the surface. Doctors wrote about pale coloring and vision challenges, but they couldn’t yet tell one type from another. As medical science evolved, careful observation showed that some people had no pigment at all, not even a little, and that their eye features and vision tended to follow a specific pattern.
In recent decades, knowledge has built on a long tradition of observation. Researchers connected this pattern to changes in a gene called TYR, which guides the body in making melanin. In Oculocutaneous albinism type 1a, this gene change stops melanin production completely—like a pigment “switch” that cannot turn on—explaining the very light hair, skin, and irises seen from birth. This insight clarified why early symptoms of Oculocutaneous albinism type 1a show up so consistently and don’t darken over time, unlike some other forms.
Once considered rare, now recognized as part of a broader spectrum of albinism, Oculocutaneous albinism type 1a became easier to identify as genetic testing developed. This allowed doctors to separate it from similar conditions and to offer clearer guidance on vision care, sun protection, and family planning. Not every early description was complete, yet together they built the foundation of today’s knowledge. Knowing the condition’s history helps explain why naming, testing, and care are more precise now than they were a generation ago.